ImmunityBio’s (IBRX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report published on Monday,Benzinga reports. The firm currently has a $30.00 price target on the stock.

A number of other analysts have also commented on IBRX. BTIG Research began coverage on ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of ImmunityBio in a research report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $12.19.

ImmunityBio Trading Down 4.1 %

IBRX stock opened at $3.01 on Monday. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -3.27 and a beta of 0.82. The firm’s 50-day moving average price is $3.13 and its two-hundred day moving average price is $3.60. ImmunityBio has a 12-month low of $2.28 and a 12-month high of $10.53.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $8.74 million. Equities analysts predict that ImmunityBio will post -0.92 EPS for the current year.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stephens Inc. AR bought a new stake in shares of ImmunityBio during the 4th quarter valued at $26,000. Cibc World Markets Corp bought a new stake in ImmunityBio during the fourth quarter worth about $35,000. Maia Wealth LLC purchased a new stake in ImmunityBio in the fourth quarter worth about $37,000. GF Fund Management CO. LTD. bought a new position in shares of ImmunityBio during the fourth quarter valued at approximately $37,000. Finally, Schechter Investment Advisors LLC purchased a new position in shares of ImmunityBio during the fourth quarter valued at approximately $38,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.